Full View

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications

N Jain, TP Umar, AF Fahner, V Gibietis - Gut Microbes, 2023 - Taylor & Francis
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …
被引用次数：27 相关文章

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications.

N Jain, TP Umar, AF Fahner, V Gibietis - Gut Microbes, 2023 - europepmc.org
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications

N Jain, TP Umar, AF Fahner, V Gibietis - Gut microbes, 2023 - pubmed.ncbi.nlm.nih.gov
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …

Advancing therapeutics for recurrent clostridioides difficile Infections: an overview of vowst's FDA approval and implications

N Jain, TP Umar, AF Fahner, V Ģībietis - Gut Microbes, 2023 - dspace.rsu.lv
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …
[HTML] nih.gov

[HTML][HTML] Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications

N Jain, TP Umar, AF Fahner, V Gibietis - Gut Microbes, 2023 - ncbi.nlm.nih.gov
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …
[PDF] rsu.lv

[PDF][PDF] Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications

N Jain, TP Umar, AF Fahner, V Gibietis - GUT, 2023 - science.rsu.lv
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …
[PDF] researchgate.net

[PDF][PDF] Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications

N Jain, TP Umar, AF Fahner, V Gibietis - GUT, 2023 - researchgate.net
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …
[PDF] researchgate.net

[PDF][PDF] Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications

N Jain, TP Umar, AF Fahner, V Gibietis - GUT, 2023 - researchgate.net
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications.

N Jain, TP Umar, AF Fahner, V Gibietis - Gut Microbes, 2023 - europepmc.org
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated
infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as …